These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30525293)

  • 1. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    Chen H; Lu W; Zhang Y; Zhu X; Zhou J; Chen Y
    Cancer Med; 2019 Jan; 8(1):383-399. PubMed ID: 30525293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
    Tian Q; Du P; Li S; Bai Z; Yang Y; Zeng J
    Medicine (Baltimore); 2017 Nov; 96(45):e8389. PubMed ID: 29137021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of biological agents in metastatic triple-negative breast cancer.
    Bramati A; Girelli S; Torri V; Farina G; Galfrascoli E; Piva S; Moretti A; Dazzani MC; Sburlati P; La Verde NM
    Cancer Treat Rev; 2014 Jun; 40(5):605-13. PubMed ID: 24529896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
    Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
    Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.
    Clark O; Botrel TE; Paladini L; Ferreira MB
    Core Evid; 2014; 9():1-11. PubMed ID: 24476748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.
    Ge L; Tang Y; Zhang QN; Tian JH; Wang XH; Pieper D; Pan B; Li L; Ling J; Bing ZT; Yang KH
    Oncotarget; 2017 Aug; 8(35):59539-59551. PubMed ID: 28938657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
    Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D
    Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
    Leung JH; Tai YS; Wang SY; Tsung-Chin H; Yip Fion HT; Chan AL; Yu-Chen H
    Expert Opin Drug Saf; 2023 Mar; 22(3):243-252. PubMed ID: 35998294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
    Yang R; Shi YY; Han XH; Liu S
    Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials.
    Zhao TT; Xu H; Xu HM; Wang ZN; Xu YY; Song YX; Yin SC; Liu XY; Miao ZF
    Gastric Cancer; 2018 May; 21(3):361-371. PubMed ID: 29455269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
    Li J; Shen G; Wang M; Huo X; Zhao F; Ren D; Zhao Y; Zhao J
    Clin Exp Med; 2023 Sep; 23(5):1489-1499. PubMed ID: 36152119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Wei C; Wang S; Ye Z; Chen Z
    Int Braz J Urol; 2018; 44(2):219-237. PubMed ID: 29211397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials.
    Li C; Hao M; Fang Z; Ding J; Duan S; Yi F; Wei Y; Zhang W
    Cancer Chemother Pharmacol; 2023 Mar; 91(3):203-217. PubMed ID: 36725727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials.
    Wang LY; Xie H; Zhou H; Yao WX; Zhao X; Wang Y
    Saudi Med J; 2017 Jan; 38(1):18-23. PubMed ID: 28042625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
    Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.